Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Imatinib has been reported to induce regression of type 2 diabetes in chronic leukemia patients. However, the mechanism of diabetes amelioration by imatinib is unknown, and it is uncertain whether imatinib has effects on type 2 diabetes itself without other confounding diseases like leukemia. We studied the effect of imatinib on diabetes in db/db mice and investigated possible mechanism's underlying improved glycemic control by imatinib. RESEARCH DESIGN AND METHODS—Glucose tolerance and insulin tolerance tests were done after daily intraperitoneal injection of 25 mg/kg imatinib into db/db and C57BL/6 mice for 4 weeks. Insulin signaling and endoplasmic reticulum stress responses were studied by Western blotting. β-Cell mass and apoptotic β-cell number were determined by combined terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) staining and insulin immunohistochemistry. The in vitro effect of imatinib was studied using HepG2 cells. RESULTS—Imatinib induced remission of diabetes in db/db mice and amelioration of insulin resistance. Expression of endoplasmic reticulum stress markers in the liver and adipose tissues of db/db mice, such as phospho-PERK, phospho-eIF2α, TRB3, CHOP, and phospho–c-Jun NH2-terminal kinase, was reduced by imatinib. Insulin receptor substrate-1 tyrosine phosphorylation and Akt phosphorylation after insulin administration were improved by imatinib. Serum aminotransferase levels and hepatic triglyceride contents were decreased by imatinib. Pancreatic β-cell mass was increased by imatinib, accompanied by decreased TUNEL+ β-cell and increased BrdU+ β-cell numbers. Imatinib attenuated endoplasmic reticulum stress in hepatoma cells in vitro. CONCLUSIONS—Imatinib ameliorated endoplasmic reticulum stress and induced remission of diabetes in db/db mice. Imatinib or related compounds could be used as therapeutic agents against type 2 diabetes and metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes
Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844 · cited 4×
“activate JNK independent of endoplasmic reticulum stress (6), thus demonstrating the specificity of the effect of imatinib on endoplasmic reticulum stress–related JNK activation (Fig.”
BackgroundInfluentialA central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“Next, we examined JNK activation because JNK activation is an important component of endoplasmic reticulum stress responses (23) and is critically involved in obesityinduced insulin resistance (7,24).”
BackgroundLocal and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., & Kahn, B. B. (2005) · Nature · doi:10.1038/nature03711 · Cited by 2,086
Mechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539
Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010 · cited 12×
“B: Insulin resistance markers in the liver and adipose tissues of db/db and C57BL/6 mice were studied by Western blotting using antibody to phospho-JNK or phospho-IRS-1 Ser307.”
BackgroundInfluentialEndoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes
Laybutt, D. R., Preston, A. M., Åkerfeldt, M. C., Kench, J. G., Busch, A. K., Biankin, A. V., & Biden, T. J. (2007) · Diabetologia · doi:10.1007/s00125-006-0590-z · Cited by 830
Solinas, G., Naugler, W., Galimi, F., Lee, M.-S., & Karin, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607626103 · Cited by 284
Self-citationEndoplasmic Reticulum Stress and Diabetes Mellitus.
ARAKI, E., OYADOMARI, S., & MORI, M. (2003) · Internal Medicine · doi:10.2169/internalmedicine.42.7 · Cited by 151 · cited 2×
“We next studied pancreatic -cell changes because pancreatic -cells have adaptive capacity to changing insulin resistance and -cell failure is the ultimate cause of diabetes (30,31).”
Background
Cited by
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Lim, Y.-M., Lim, H., Hur, K. Y., Quan, W., Lee, H.-Y., Cheon, H., Ryu, D., Koo, S.-H., Kim, H. L., Kim, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms5934 · Cited by 189
Self-citationLiubaoerjijin, Y., Terada, T., Fletcher, K., & Boulé, N. G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0870-0 · Cited by 145
Wu, Q., Yang, F., An, Q., Liu, Y., Tian, H., Du, Y., Cai, W., Lei, M., Xu, J., Deng, L., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049987
Metadata
- Authors
- Han, M. S., Chung, K. W., Cheon, H. G., Rhee, S. D., Yoon, C.-H., Lee, M.-K., Kim, K.-W., & Lee, M.-S.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-02-01
- Volume
- 58
- Issue
- 2
- Pages
- 329-336
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2143076346
- Cited by
- 120
- References
- 10
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.